Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 226

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 226
---
   |            |    |     | Grant Date |           |     | Exercise 
 Price    
 per      
 Share    
 (£)      |       |     | Expiration 
 Date       |           |
| Stephen Stamp                                |     |           |      1,500 | -1 |     |            |  9/9/2019 |     |          | 21.00 |     |            |  9/9/2029 |
|                                              |     |           |     15,000 | -2 |     |            | 6/17/2020 |     |          |  4.04 |     |            | 1/17/2030 |
|                                              |     |           |     25,000 | -2 |     |            | 7/15/2021 |     |          |  5.55 |     |            | 7/14/2031 |
|                                              |     |           | 85,922,000 | -2 |     |            | 7/10/2024 |     |          | 0.003 |     |            | 7/10/2034 |
| All senior management as a group (2 persons) |     |           | 85,958,813 | -4 |     |            |        -5 |     |          |    -6 |     |            |        -7 |

_________

| (1) | Of these options, 375 previously vested on September 9, 2020, and the remaining 1,125 options have subsequently 
 vested, or will vest, in 12 equal quarterly tranches, over a subsequent three-year period.                      |

| (2) | Of these options, 25% of the options vest 12 months after the grant date, and the remaining options have 
 subsequently vested, or will vest, in 12 equal quarterly tranches over a subsequent three-year period.   |

| (3) | All of Dr. Zamoryakhin have expired. |

| (4) | 36,813 stock options are fully vested. |

| (5) | The grant dates range from September 9, 2019 to July 10, 2024. |

| (6) | The exercise price of the options range from £0.003 to £5.55. |

| (7) | The stock options expire between September 9, 2029 and July 10, 2034